Literature DB >> 25576527

Paraneoplastic leukemoid reaction in a patient with BRAF V600E-mutated metastatic malignant melanoma.

Emanuel Gouveia1, Mónica Sousa1, Maria José Passos1, António Moreira1.   

Abstract

A paraneoplastic leukemoid reaction is a rare condition of extreme leucocytosis in patients with solid malignancies. The differential diagnosis is often a true challenge. We present a case of a 56-year old woman with a history of stage IIIA malignant melanoma resected in 2004 that was diagnosed in May 2013 with BRAF V600E-mutated metastatic disease (left arm mass, lungs and adrenal glands). The laboratory findings revealed leucocytosis with granulocytosis that increased progressively to values up to 120.0 × 10(9)/L. After a diagnostic work-up, a diagnosis of a paraneoplastic leukemoid reaction was established. We report the response of leucocytosis to radiation and BRAF inhibitor therapy, albeit short-lived. To the best of our knowledge, this is the first case report of a paraneoplastic leukemoid reaction in metastatic melanoma with characterisation of BRAF V600 mutation status. It remains unclear whether the aggressive tumour phenotype is related to the leukemoid reaction and whether this is related to the BRAF mutation. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25576527      PMCID: PMC4289760          DOI: 10.1136/bcr-2014-208645

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  17 in total

Review 1.  Paraneoplastic granulocytosis in metastatic melanoma.

Authors:  Jeremy L Davis; R Taylor Ripley; Timothy L Frankel; Irina Maric; Jay N Lozier; Steven A Rosenberg
Journal:  Melanoma Res       Date:  2010-08       Impact factor: 3.599

2.  Bladder cancer producing granulocyte colony-stimulating factor.

Authors:  N Ito; T Matsuda; Y Kakehi; E Takeuchi; T Takahashi; O Yoshida
Journal:  N Engl J Med       Date:  1990-12-13       Impact factor: 91.245

3.  Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma.

Authors:  I Kasuga; S Makino; H Kiyokawa; H Katoh; Y Ebihara; K Ohyashiki
Journal:  Cancer       Date:  2001-11-01       Impact factor: 6.860

4.  Leukocytosis due to adrenal metastases from malignant melanoma: reversal after bilateral adrenalectomy with long-term survival.

Authors:  R W Carey; V S Kunz
Journal:  Am J Hematol       Date:  1988-03       Impact factor: 10.047

5.  An update on the etiology and diagnostic evaluation of a leukemoid reaction.

Authors:  Vissaria Sakka; Sotirios Tsiodras; Evangelos J Giamarellos-Bourboulis; Helen Giamarellou
Journal:  Eur J Intern Med       Date:  2006-10       Impact factor: 4.487

6.  Intense paraneoplastic neutrophilic leukemoid reaction related to a G-CSF-secreting lung sarcoma.

Authors:  Fabrice Jardin; Marc Vasse; Marc Debled; Stéphane Dominique; Philippe Courville; Françoise Callonnec; Gérard Buchonnet; Luc Thiberville; Hervé Tilly
Journal:  Am J Hematol       Date:  2005-11       Impact factor: 10.047

7.  Leukemoid reaction response to chemotherapy and radiotherapy in a patient with cervical carcinoma.

Authors:  H S Nimieri; S N Makoni; F H Madziwa; D S Nemiary
Journal:  Ann Hematol       Date:  2003-03-20       Impact factor: 3.673

8.  Production of granulocyte colony-stimulating factor by a human melanoma cell line.

Authors:  M B Lilly; P E Devlin; J J Devlin; T A Rado
Journal:  Exp Hematol       Date:  1987-10       Impact factor: 3.084

9.  Extreme leucocytosis and splenomegaly in metastasised melanoma.

Authors:  J F de Wolff; E V Planken; G J den Ottolander
Journal:  Neth J Med       Date:  2004-05       Impact factor: 1.422

10.  Leukemoid reaction: a rare paraneoplastic syndrome associated with advanced bladder carcinoma.

Authors:  J I Miller; R G Sarver; G W Drach
Journal:  Urology       Date:  1994-09       Impact factor: 2.649

View more
  2 in total

1.  Melanoma induced immunosuppression is mediated by hematopoietic dysregulation.

Authors:  Neha Kamran; Youping Li; Maria Sierra; Mahmoud S Alghamri; Padma Kadiyala; Henry D Appelman; Marta Edwards; Pedro R Lowenstein; Maria G Castro
Journal:  Oncoimmunology       Date:  2017-12-14       Impact factor: 8.110

2.  BRAF V600Q-mutated lung adenocarcinoma with duodenal metastasis and extreme leukocytosis.

Authors:  Ayman Qasrawi; Addison Tolentino; Mouhanna Abu Ghanimeh; Omar Abughanimeh; Sakher Albadarin
Journal:  World J Clin Oncol       Date:  2017-08-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.